No Data
Limin Group (002734.SZ): Signed a global strategy cooperation agreement with The Cigna Group.
On December 20th, Gelonghui reported that Limin Group (002734.SZ) announced that on December 19, 2024, the company signed a "Global Strategy Cooperation Agreement" with Chengdu Green Cigna Biotechnology Co., Ltd. (hereinafter referred to as "Green Cigna Biotechnology"). Both parties will focus on new biopesticides based on underlying technologies such as small peptide extraction, molecular modification, and synthetic biology, jointly creating, researching, and promoting new agricultural small peptide biological products.
Limin Group (002734.SZ): Limin Chemical has been recognized as a high-tech enterprise.
Liming Group (002734.SZ) announced recently that the national "High-tech Enterprise Recognition Management Work Website" published...
Limin Group (002734.SZ): has a production capacity of 6000 tons of glufosinate-ammonium and 2000 tons of bio-based refined glufosinate-ammonium.
On December 4, Gelonghui reported that Limin Group (002734.SZ) stated in a recent investor relations activity that the company's layout in herbicides is relatively small, with a glyphosate production capacity of 6,000 tons, a bio-based refined glyphosate capacity of 2,000 tons, a nitrosulfonylacetic acid capacity of 1,000 tons, and a cyclic sulfonamide capacity of 500 tons. Currently, herbicide products are at historically low prices, and product prices and gross margins will face certain pressure for a period of time. Limin Group continues to increase investment in technology research and development, continuously improving existing products through technological transformation, cost reduction, and efficiency enhancement to strengthen product competitiveness. The company remains bullish on glyphosate.
Limin Group (002734.SZ): Core products include Daisen manganese zinc, Baijuns clear, performing well in the market.
Gelonghui December 4th | limin group (002734.SZ) stated in recent investor relations activities that the company's core products include Daisen manganese zinc, Baijunclear, etc., with good market performance. After acquiring Weiyuan Biochemistry, the company strengthened its insecticide business, owning the third-ranked domestic production capacity of avermectin and 800 tons of methomyl salt. The market fill price of avermectin rose from 0.35-0.36 million yuan at the end of last year to 0.46 million yuan, an increase of nearly 30%. The price of methomyl salt rose from 0.46 million yuan to 0.65-0.66 million yuan, with the price of 95% concentration products performing better.
Can Limin Group Co.,Ltd.'s (SZSE:002734) Weak Financials Pull The Plug On The Stock's Current Momentum On Its Share Price?
Limin Group (002734.SZ): During the current period, the market for the raw material of Bacillus thuringiensis is in short supply.
Gelonghui reported on November 26 that limin group (002734.SZ) stated on the investor interaction platform that the market for the original drug Baijunqing is in short supply, leading to price increases, while the prices of major raw materials remain stable. The company's subsidiary, Xinhahe, has a production capacity of 0.03 million tons per year, accounting for about 47% of the global capacity. Currently, the company's products are in a scheduled delivery status, and market demand and price expectations are optimistic.
What You Can Learn From Limin Group Co.,Ltd.'s (SZSE:002734) P/E
